Evolution of Initial Treatment for Desmoid Tumors.
Active surveillance
Cryoablation
Desmoid tumors
Initial treatment
Treatment-free survival
Tyrosine kinase inhibitors
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
13
05
2024
accepted:
16
07
2024
medline:
12
8
2024
pubmed:
12
8
2024
entrez:
12
8
2024
Statut:
aheadofprint
Résumé
Desmoid tumors (DTs) are rare, fibroblastic cell proliferations that can exhibit locally aggressive behavior but lack metastatic potential. Initial management has traditionally involved upfront resection; however, contemporary guidelines and expert panels have increasingly advocated for prioritizing active surveillance strategies. A single-institution, retrospective chart review identified all patients diagnosed with a primary DT at any site from 2007 to 2020. The primary outcome was the initial management strategy over time. Secondary outcomes included treatment-free survival (TFS) and time to treatment (TTT) for those undergoing active surveillance, as well as recurrence-free survival (RFS) and time to recurrence for those undergoing resection. Overall, 103 patients were included, with 68% female and a median follow-up of 44 months [24-74]. The most common tumor locations included the abdominal wall (27%), intra-abdominal/mesenteric (25%), chest wall (19%), and extremity (10%). Initial management included resection (60%), systemic therapy (20%), active surveillance (18%), and cryoablation (2%). Rates of surgical resection significantly decreased (p < 0.001) over time, from 69.6% prior to 2018 to 29.2% after 2018. For those treated with upfront resection, 5-year RFS was 41.2%, and for patients undergoing initial active surveillance, TFS was 66.7% at 2 years, with a median TTT of 4 months [4-10]. This single-institution cohort at a tertiary medical center spanning over a decade demonstrates the transition to active surveillance for initial management of DTs, and highlights salient metrics in the era of surveillance. This trend mirrors recommended treatment strategies by expert panels and consensus guidelines.
Identifiants
pubmed: 39133446
doi: 10.1245/s10434-024-15938-x
pii: 10.1245/s10434-024-15938-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Society of Surgical Oncology.
Références
Escobar C, Munker R, Thomas JO, Li BD, Burton GV. Update on desmoid tumors. Ann Oncol. 2012;23:562–9.
doi: 10.1093/annonc/mdr386
pubmed: 21859899
Riedel RF, Agulnik M. Evolving strategies for management of desmoid tumor. Cancer. 2022;128:3027–40.
doi: 10.1002/cncr.34332
pubmed: 35670122
Shields CJ, Winter DC, Kirwan WO, Redmond HP. Desmoid tumours. Eur J Surg Oncol. 2001;27:701–6.
doi: 10.1053/ejso.2001.1169
pubmed: 11735163
Nieuwenhuis MH, Casparie M, Mathus-Vliegen LMH, Dekkers OM, Hogendoorn PCW, Vasen HFA. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129:256–61.
doi: 10.1002/ijc.25664
pubmed: 20830713
Federman. Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition. NPJ Precis Oncol. 2022;6:62.
Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise—a sarcoma patients EuroNet and European organisation for research and treatment of cancer/soft tissue and bone sarcoma group I. Eur J Cancer. 2015;51:127–36.
doi: 10.1016/j.ejca.2014.11.005
pubmed: 25434922
Napolitano A, Mazzocca A, Spalato Ceruso M, Minelli A, Baldo F, Badalamenti G, et al. Recent advances in desmoid tumor therapy. Cancers (Basel). 2020;12:2135.
doi: 10.3390/cancers12082135
pubmed: 32752153
pmcid: 7463981
Ballo MT, Zagars GK, Pollack A, Pisters PWT, Pollock RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999;17:158.
doi: 10.1200/JCO.1999.17.1.158
pubmed: 10458229
Merchant NB, Lewis JJ, Woodruff JM, Leung DHY, Brennan MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999;86:2045–52.
doi: 10.1002/(SICI)1097-0142(19991115)86:10<2045::AID-CNCR23>3.0.CO;2-F
pubmed: 10570430
Mullen JT, DeLaney TF, Kobayashi WK, Szymonifka J, Yeap BY, Chen Y-L, et al. Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol. 2012;19:4028–35.
doi: 10.1245/s10434-012-2638-2
pubmed: 22965569
Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PWT, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785–91.
doi: 10.1200/JCO.2006.10.5015
pubmed: 17470870
Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20:4096–102.
doi: 10.1245/s10434-013-3197-x
pubmed: 24052312
Gounder M, Ratan R, Alcindor T, Schöffski P, Van Der Graaf WT, Wilky BA, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898–912.
doi: 10.1056/NEJMoa2210140
pubmed: 36884323
pmcid: 11225596
van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22:2817–23. https://doi.org/10.1245/s10434-015-4632-y .
doi: 10.1245/s10434-015-4632-y
pubmed: 26045393
pmcid: 4531142
Sobczuk Pawełand Agnieszczak IM, Grycuk W, Czarnecka AM, Świtaj T, Koseła-Paterczyk H, Morysiński T, et al. What is the best front-line approach in patients with desmoid fibromatosis? A retrospective analysis from a reference center. Eur J Surg Oncol. 2022;47:2602–8.
Alman B, Attia S, Baumgarten C, Benson C, Blay J-Y, Bonvalot S, et al. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96–107.
doi: 10.1016/j.ejca.2019.11.013
StataCorp LLC. Stata statistical software: release 17. College Station: StataCorp LLC; 2021.
Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the french sarcoma group. Eur J Cancer. 2017;83:125–31.
doi: 10.1016/j.ejca.2017.06.017
pubmed: 28735069
Anneberg M, Svane HML, Fryzek J, Nicholson G, White JB, Edris B, et al. The epidemiology of desmoid tumors in Denmark. Cancer Epidemiol. 2022;77:102114.
doi: 10.1016/j.canep.2022.102114
pubmed: 35121405
Nishida Y, Kawai A, Toguchida J, Ogose A, Ae K, Kunisada T, et al. Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan. Int J Clin Oncol. 2019;24:1498–505.
doi: 10.1007/s10147-019-01512-z
pubmed: 31332613
Peng PD, Hyder O, Mavros MN, Turley R, Groeschl R, Firoozmand A, et al. Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients. Ann Surg Oncol. 2012;19:4036–42.
doi: 10.1245/s10434-012-2634-6
pubmed: 22972507
pmcid: 3568525
Timbergen MJM, Schut A-RW, Grünhagen DJ, Sleijfer S, Verhoef C. Active surveillance in desmoid-type fibromatosis: a systematic literature review. Eur J Cancer. 2020;137:18–29.
Houdt WJ Van, Husson O, Patel A, Jones RL, Smith MJF, Miah AB, et al. Outcome of primary desmoid tumors at all anatomic locations initially managed with active surveillance. Ann Surg Oncol. 2019;26:4699–706. https://doi.org/10.1245/s10434-019-07826-6 .
Cassidy MR, Lefkowitz RA, Long N, Qin L-X, Kirane A, Sbaity E, et al. Association of MRI T2 signal intensity with desmoid tumor progression during active observation: a retrospective cohort study. Ann Surg. 2020;271(4):748–55.
doi: 10.1097/SLA.0000000000003073
pubmed: 30418203
Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honorè C, et al. Spontaneous regression of primary abdominal wall desmoid tumors : more common than previously thought. Ann Surg Oncol. 2013;20:4096–102. https://doi.org/10.1245/s10434-013-3197-x .
doi: 10.1245/s10434-013-3197-x
pubmed: 24052312
Colombo C, Miceli R, Le Péchoux C, Palassini E, Honoré C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer. 2015;51:186–92.
doi: 10.1016/j.ejca.2014.11.019
pubmed: 25500145
Schmitz JJ, Schmit GD, Atwell TD, Callstrom MR, Weisbrod AJ, Morris JM. Percutaneous cryoablation of extraabdominal desmoid tumors: a 10-year experience. Am J Roentgenology. 2016;207(1):190–5. https://doi.org/10.2214/AJR.15.14391 .
doi: 10.2214/AJR.15.14391
Bouhamama A, Wdowik Q, Grillet F, Brahmi M, Sunyach MP, Vaz G, et al. Prognostic factors for local recurrence after cryoablation of desmoid tumors. J Vasc Interv Radiol. 2023;34:1538–46.
doi: 10.1016/j.jvir.2023.05.012
pubmed: 37182669
Kurtz J-E, Buy X, Deschamps F, Sauleau E, Bouhamama A, Toulmonde M, et al. CRYODESMO-O1: a prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. Eur J Cancer. 2021;143:78–87.
doi: 10.1016/j.ejca.2020.10.035
pubmed: 33290994